Actipulse Neuroscience

actipulseneuroscience.com →

-52%

est. 2Y upside i

Seed

Bringing non-invasive brain stimulation from the hospital to the home

Rank

#1936

Sector

Neurotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Actipulse Neuroscience presents a high-risk, high-reward equity opportunity, hinging on its ability to secure FDA approval for its at-home device and differentiate itself in a market where a direct competitor has already gained regulatory clearance.

Last updated: February 16, 2026

Bull (18%)+350%

Actipulse successfully secures FDA approval for its at-home MDD device by late 2026, demonstrates strong early market adoption despite competition, and attracts a strategic acquisition at a significant premium.

Base (37%)+75%

FDA approval for the at-home MDD device is delayed or market penetration is slower than anticipated due to incumbent competition, leading to a modest valuation increase through a later funding round or smaller acquisition.

Bear (45%)-90%

Clinical trials fail, FDA approval is not granted, or Actipulse struggles to compete with already-approved at-home devices, leading to a significant loss of value or company failure.

Est. time to liquidity~4.0 years

Other — 2 roles

View all 2 open roles at Actipulse Neuroscience →

Last updated: February 17, 2026

Community

Valuation Sentiment

Our model estimates -52% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.